The move positions IHH to increase its holding to approximately 57%, marking a significant milestone in its strategic expansion across India’s dynamic healthcare sector.

Investor optimism soars as IHH Healthcare secures regulatory approval for Fortis takeover, signaling strengthened healthcare presence and expansion across India.

IHH (IHHH.KL) climbed 3.1% to 8.38 ringgit ($1.99) on the Malaysian stock exchange, while Fortis (FOHE.NS) soared 6.7% to 1,045.95 rupees, outperforming domestic benchmarks. The gains underscore strong investor confidence and highlight the market’s positive reception of the deal, which has been eagerly anticipated since 2018.

The approval revives a strategic initiative that will strengthen IHH’s operational footprint and enhance healthcare delivery across India. By integrating Fortis’ 33 healthcare facilities, which house over 5,700 beds across 11 states, IHH is set to create a robust network offering high-quality, accessible healthcare to millions of patients nationwide.

Analysts view the approval as a key turning point for both companies. “This milestone signals IHH’s commitment to expanding its presence in India and supporting Fortis in reaching new heights in patient care, medical excellence, and operational efficiency,” noted Nursuhaiza Hashim, equity analyst at BIMB Securities Research.

The successful regulatory clearance is expected to foster long-term value creation for shareholders, employees, and the communities these hospitals serve.

The strategic move also highlights IHH’s growing international footprint. Operating more than 80 hospitals across 10 countries, including Malaysia, Singapore, Türkiye, and India, IHH continues to solidify its position as one of the world’s leading private healthcare providers. The addition of Fortis further strengthens its network, ensuring enhanced healthcare accessibility and world-class medical services across the region.

Fortis, renowned for its high standards in patient care, specialized services, and modern facilities, stands to benefit from IHH’s expertise in operational management and international healthcare best practices. The collaboration between these two healthcare leaders promises a new era of innovation, efficiency, and service quality in India’s growing healthcare market.

Investor enthusiasm reflects confidence in the potential for synergistic growth. Both IHH and Fortis shares have outperformed major indices, signaling strong market sentiment and faith in the long-term benefits of this strategic acquisition. The deal also represents a clear signal to global investors that India’s healthcare sector remains an attractive, high-growth market.

Looking ahead, the expanded IHH-Fortis network is expected to drive improvements in healthcare infrastructure, enhance patient experiences, and facilitate access to cutting-edge treatments and specialized care. The merger positions both companies to take advantage of India’s growing demand for quality healthcare services while delivering sustainable growth and value creation for stakeholders.

This landmark approval is more than just a regulatory milestone—it reflects IHH’s unwavering commitment to strengthening healthcare across India, delivering innovative solutions, and fostering a healthier future for communities nationwide. The strategic integration of Fortis into IHH’s global network demonstrates forward-looking leadership and sets the stage for continued growth and success in the region.

With a strengthened presence and growing capabilities, IHH Healthcare and Fortis are poised to elevate standards of healthcare delivery, ensuring patients across India benefit from world-class medical care while investors enjoy confidence in a robust, forward-looking healthcare ecosystem.

The summit opened with a heartfelt tribute to the Hunter Syndrome warriors who have lost their lives to this challenging disease. Their legacy served as a powerful reminder of the ongoing need for accessible treatment, research, and policy implementation in India’s rare disease ecosystem.

Prof. (Dr.) Shefali Gulati of AIIMS, New Delhi, and member of the Central Technical Committee for Rare Diseases (CTCRD), stressed the importance of collaboration across all stakeholders. She called for a coordinated approach that strengthens advocacy, improves patient care, and ensures efficient execution of rare disease policies.

Mr. Saurabh Singh, Co-founder and Director of the Rare Diseases India Foundation (RDIF), highlighted gaps in the implementation of the National Rare Disease Policy 2021 (NRDP). While Hunter Syndrome is officially recognized, financial support under the policy remains insufficient, and treatment costs continue to pose major challenges for families.

He emphasized that the Rs. 50 lakh assistance under NRDP does not meet the realities of treatment, which often costs crores. Patients face barriers to support, especially in private hospitals, and Ayushman Bharat Yojna benefits are limited to BPL families, leaving many patients without coverage.

Mr. Singh also pointed out the lack of caregiver support and the absence of insurance coverage for rare diseases. Limited research in India further prevents cost reduction for life-saving therapies. Judicial delays in some cases deny children their fundamental right to life under Article 21 of the Constitution, underscoring the urgency of policy action.

He drew attention to the specific challenges faced by dependents of Defence personnel and CGHS beneficiaries, where delays in drug procurement can create treatment gaps of three to six months. Despite funding allocations, bureaucratic inefficiencies continue to put lives at risk.

Drawing a parallel with India’s rapid COVID-19 vaccine development, Mr. Singh questioned why progress on rare diseases has lagged over the past 12 years. In an emotional and inspiring moment, he shared the recent loss of his 13-year-old son, Shaurya, to Hunter Syndrome.

Yet, Mr. Singh’s resolve remains unshaken. He declared, “My fight will continue until medicines become affordable or free for every rare disease patient in this country. My work will be my eternal tribute to Shaurya.” His courage resonated deeply with attendees and symbolized the collective hope and determination of countless families across India.

Ex-Serviceman HAV. D.K. Chansolia also shared his experience navigating the Defence healthcare system to procure life-saving drugs for his son. He spoke about procedural delays and the shortage of specialized experts, highlighting the need for systemic reforms.

The summit concluded with a united call to the Government and the Hon’ble Supreme Court to address these challenges urgently. Participants emphasized that timely intervention, policy support, and collaborative efforts are key to transforming the lives of rare disease patients across India.

The National Hunter Alliance Summit 2025 showcased resilience, solidarity, and the collective commitment of India’s rare disease community. It marked a significant step toward building a future where every patient has access to life-saving treatment, support, and dignity.